Market Place
Sourcing Support
AMO Outlines AMO-02 Myotonic Dystrophy Development Post-FDA Meet
02 May 2024 //
PR NEWSWIRE
AMO Pharma Announces Collaboration with Population Health Research Institute
15 Feb 2024 //
PR NEWSWIRE
AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function
19 Sep 2023 //
PR NEWSWIRE
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02
06 Sep 2023 //
PR NEWSWIRE
AMO Pharma Announces Completion of Treatment of Last Patient
25 Apr 2023 //
PR NEWSWIRE
AMO Announces MHRA Confirmation of CDM1-RS as Measure in Myotonic Dystrophy
27 Feb 2023 //
PR NEWSWIRE
AMO Pharma Announces Completion of Enrollment in REACH-CDM Study
06 Dec 2022 //
PRNEWSWIRE
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in CMD1
22 Dec 2021 //
PRNEWSWIRE
Julia Jones Joins AMO Pharma As Chief Financial Officer And Board Member
14 Oct 2021 //
PRNEWSWIRE
AMO Pharma Announces First Patient Enrolled In REACH-CDM
30 Sep 2021 //
PRNEWSWIRE
AMO Pharma Announces Activation of Additional Trial Sites for Pivotal REACH
17 May 2021 //
PRNEWSWIRE
AMO Pharma Announces Activation of Additional Trial Sites for Pivotal REACH-CDM
17 May 2021 //
PRNEWSWIRE
AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02
22 Dec 2020 //
PRNEWSWIRE
AMO Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02
22 Dec 2020 //
PRNEWSWIRE
AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02
22 Dec 2020 //
PRNEWSWIRE
AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02
22 Dec 2020 //
PRNEWSWIRE
FDA Grants Rare Pediatric Disease Designation to AMO for AMO-02
09 Nov 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.